• Criptomonedas
  • Mercados de Predicción
  • Noticias
  • Trading Agéntico
  • Artículos
  • Ligas

Buscar Criptomonedas

Criptomonedas de tendencia

CoinRithm

Empresa

Entidad legal
Bees-x Limited
Número de empresa
13308136
Constituida en
England and Wales
Domicilio social
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm es un servicio de información e investigación operado por Bees-x Limited. No está autorizado por la Financial Conduct Authority (FCA) para realizar actividades reguladas, y nada en este sitio constituye asesoramiento financiero.

Explorar

CriptomonedasMercados de PredicciónNoticiasArtículosAgent ArenaLigas

Funciones

TableroComercio SimuladoTrading AgénticoPortafolioLista de SeguimientoConfiguraciones

Empresa

Sobre NosotrosMetodologiaTérminos de UsoPolítica de PrivacidadPolítica de CookiesDescargo de Responsabilidad

Soporte

Contacto SoporteFAQKit para desarrolladoresDocumentación MCP

Sociales

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Reservados todos los derechos.
Disponible en Google PlayDescargar en App Store
  • Inicio
  • MercadosMercados de Predicción
  • Noticias
  • Tablero
  1. Mercados de Predicción
  2. Health & Medicine
  3. FDA approves Merck's Welireg + Keytruda or Keytruda Qlex?
FDA approves Merck's Welireg + Keytruda or Keytruda Qlex?

FDA approves Merck's Welireg + Keytruda or Keytruda Qlex?

2.0% (24h)Health & MedicineOne-Off7d
PolymarketPolymarketComprobar disponibilidadSin KYC2% de comisión
Probabilidad implícita actual
Sí
Sí 83%+0.0%
Calidad del mercado

49 / 100

Baja calidad
Volumen 24h

11,9 €

Liquidez

305,5 €

Baja liquidez
Compra / Venta

82.0% / 84.0%

Spread

2.4%

Spread estrecho
Datos de mercado

Actualizado hace 5 minutos

4 jun 26, 19:3519 jun 26, 0:00

Tendencias

Resultado24hProbabilidad

Resultado elegido

Yes83%

Reglas

As of market creation, the FDA's expected decision date for the specified application is June 19, 2026.

Polymarket
  • This market will resolve to "Yes" if the U.S.
  • Food and Drug Administration (FDA) grants full or conditional approval for Merck's Welireg + Keytruda or Keytruda Qlex as a treatment for adjuvant treatment of clear cell renal cell carcinoma following nephrectomy by July 3, 2026, 11:59 PM ET.
  • Otherwise, this market will resolve to "No."
  • An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
  • The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

Mercados Relacionados

Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

145,3 mil €
Sí: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

16,6 mil €
Sí: 10%PolymarketPOLYMARKET
Ebola pandemic in 2026?

Ebola pandemic in 2026?

8,7 mil €
Sí: 8%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

1,3 mil €
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Which disease will be eradicated next in humans?

462,5 €
Polio: 26.7%Manifold MarketsMANIFOLD MARKETS
When, where or how will Trump die?

When, where or how will Trump die?

137,8 €
2025: 0%Manifold MarketsMANIFOLD MARKETS

Activos en estos temas

BitcoinBTC$62,978.79+2.53%EthereumETH$1,661.11+1.78%SolanaSOL$65.42+1.74%DogecoinDOGE$0.0851+1.56%XRPXRP$1.12+0.44%BNBBNB$597.15+1.83%

Noticias Relacionadas

Chainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.NewsBrian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto News

Reglas

As of market creation, the FDA's expected decision date for the specified application is June 19, 2026.

Polymarket
  • This market will resolve to "Yes" if the U.S.
  • Food and Drug Administration (FDA) grants full or conditional approval for Merck's Welireg + Keytruda or Keytruda Qlex as a treatment for adjuvant treatment of clear cell renal cell carcinoma following nephrectomy by July 3, 2026, 11:59 PM ET.
  • Otherwise, this market will resolve to "No."
  • An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
  • The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs